Responses
Regular and young investigator award abstracts
Combination immunotherapies
469 Cooperation between checkpoint inhibitors targeting the PD-1/PD-L1 axis and ATRC-101, a novel clinical-stage candidate for the treatment of solid tissue malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.